Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26684538 | 0.91 | HRH4 (0.45) | ACHEHRH4HTR7 | |
| SCHEMBL20756582 | 0.83 | LDHA (0.42) | ACHEHRH4 | |
| SCHEMBL24126677 | 0.82 | ACHE (0.41) | ACHEHRH4PREPFAP | |
| SCHEMBL23152497 | 0.80 | HTR7 (0.46) | HRH4HTR7CYP17A1 | |
| SCHEMBL2272239 | 0.80 | HTR3E (0.47) | HRH4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL24126674 | 0.78 | CHRM1 (0.41) | ACHEHRH4 | |
| Hydrochloric Acid SCHEMBL2272152 | 0.78 | HTR3E (0.46) | HRH4PSEN1PSEN2APH1BNCSTN | |
| Hydrochloric Acid SCHEMBL16684961 | 0.78 | HTR3E (0.46) | HRH4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL26684427 | 0.77 | ACACB (0.42) | ACHEHRH4 | |
| SCHEMBL13034802 | 0.77 | CHKA (0.53) | ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | SATO PHARMACEUTICAL CO., LTD. (JP) | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339937-A1 | CONDENSED RING COMPOUNDS THAT INHIBIT H-PGDS | HPGDS, PTGS1, PTGIS | ACHE 3701/4885HRH4 58/4885PSEN1 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.